TICKERNERD
Menu
ABBVABBVHealthcare · Drug Manufacturers - General

ABBV Stock Forecast: AbbVie, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$257
+0.83% on the day

The 31 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $282 — +9.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$454.4B
Ticker Nerd rank
96 / 100
Median analyst target
$282
Analysts covering
31
Revenue$17.0B+10.2% y/y
Operating income$6.7B
Net income$3.6B
Free cash flow$3.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
+2.8%
YTD
+15.2%
1Y
+20.4%
From 52W high
−3.3%
From 52W low
+31.2%
$196
$266
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABBV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Accruals
90
Value
87
Quality
86
Momentum
83
Growth
80
Revisions
71
Issuance
61
Size
0

Volatility (100): The share price has been relatively steady.

Issuance (61): The company has been issuing shares or taking on financing, diluting existing holders.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABBV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26ABBVHigh $328Median $282Low $200

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says31 analysts
25 Buy5 Hold1 Sell
Low $200Median $282High $328

The green dot is the last close — the median target sits +9.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsBuy$300 → $315
20 Aug 2026Piper SandlerMaintainsOverweight$298 → $303
20 Aug 2026Piper SandlerMaintainsOverweight—
17 Aug 2026Wells FargoMaintainsOverweight—
17 Aug 2026Wells FargoMaintainsOverweight$295 → $300
13 Aug 2026Wolfe ResearchUpgradeOutperform$300
13 Aug 2026Wolfe ResearchUpgradeOutperform—
11 Aug 2026BNP ParibasMaintainsNeutral$218 → $247
11 Aug 2026BNP ParibasMaintainsNeutral—
10 Aug 2026Evercore ISI GroupMaintainsOutperform—
10 Aug 2026Evercore ISI GroupMaintainsOutperform$246 → $260
6 Aug 2026BerenbergMaintainsBuy—
5 Aug 2026Erste GroupUpgradeBuy—
4 Aug 2026GuggenheimMaintainsBuy$261 → $288
4 Aug 2026GuggenheimMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$282 → $290
3 Aug 2026Cantor FitzgeraldMaintainsOverweight—
3 Aug 2026Cantor FitzgeraldMaintainsOverweight$265 → $285
3 Aug 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABBV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABBV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, AbbVie, Inc. returned +20.4% against +17.5% for the S&P 500, dividends included.

ABBV vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26ABBVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABBV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.6%
Analysts raising
1
Analysts cutting
20
Fundamentals

AbbVie, Inc. (ABBV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
72.4×

Cheaper than 10% of US stocks

Price / sales
7.1×

Cheaper than 18% of US stocks

Price / book
−77.2×

Cheaper than 99% of US stocks

EV / EBITDA
16.9×

Cheaper than 19% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
285.2%

Higher than 92% of US stocks

Gross margin
74.7%

Higher than 87% of US stocks

Operating margin
40.0%

Higher than 92% of US stocks

Net margin
9.8%

Higher than 69% of US stocks

Returns & dividend
Return on equity
−129.7%

Higher than 11% of US stocks

Return on assets
10.5%

Higher than 93% of US stocks

Dividend yield
2.7%

Higher than 58% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AbbVie, Inc. (ABBV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AbbVie, Inc. has a market value of $454.4B and an enterprise value of $518.7B.

  • Revenue in the twelve months to 30 June 2026: $64.4B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: $6.3B, a 9.8% net margin.

  • Diluted earnings per share, trailing twelve months: $3.54.

  • Free cash flow in the twelve months to 30 June 2026: $18.2B.

  • AbbVie, Inc. spent $1.5B on share buybacks and $12.0B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.8B.

  • Trailing P/E: 72.4×; forward P/E: 15.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.69%, paying out 190% of earnings.

  • AbbVie, Inc. employs 57,000 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ABBV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
ABBVAbbVie, Inc.$454.4B
96
MRKMerck & Co., Inc.$357.2B
82
JNJJohnson & Johnson$640.0B
91
AMGNAmgen, Inc.$203.4B
90
LLYEli Lilly & Co.$1.1T
90
GILDGilead Sciences, Inc.$178.4B
93
PFEPfizer Inc.$157.6B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABBV news & analysis

Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

The Motley Fool · 12 Sept 2026neutral

Billionaire investor Israel "Izzy" Englander more than doubled his stake in AbbVie stock, according to a Motley Fool article. The report also notes AbbVie is a diversified pharmaceutical company with a growing dividend that currently yields 2.7%.

Why it matters — A prominent billionaire investor increasing his position is noteworthy activity for AbbVie watchers tracking major institutional ownership and confidence in the stock.

AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

Zacks Investment Research · 11 Sept 2026positive

AbbVie's atogepant delivered positive data from the late-stage LUNA study in menstrual migraine, meeting its study goal. The result could expand the company's migraine franchise and address an unmet patient need.

Why it matters — Positive late-stage data for atogepant could broaden AbbVie's migraine product portfolio and open a new treatment opportunity in menstrual migraine.

What's Going On With AbbVie Stock Friday?

Benzinga · 11 Sept 2026positive

AbbVie shares edged higher Friday morning following Thursday's announcement of positive Phase 3 trial results for atogepant, its menstrual migraine treatment. The news prompted investor attention to the company's pipeline progress.

Why it matters — Positive Phase 3 results for atogepant could strengthen AbbVie's migraine portfolio and support future growth prospects for ABBV watchers.

How Much Dividend Income Can You Buy With $250,000?

24/7 Wall Street · 11 Sept 2026neutral

The article examines how much dividend income a $250,000 rollover can generate, noting that yield alone is not the full picture and that only one company on its list exceeds the current Treasury rate. It evaluates dividend-paying stocks in this context.

Why it matters — An AbbVie watcher would care because the piece assesses dividend yields against Treasury rates, which helps frame ABBV's income appeal for dividend-focused investors.

AbbVie Declares Quarterly Dividend

PRNewsWire · 10 Sept 2026neutral

AbbVie's board of directors declared a quarterly cash dividend of $1.73 per share, as announced on Sept. 10, 2026 from North Chicago, Ill. The dividend declaration is reported via PRNewswire.

Why it matters — A shareholder or AbbVie watcher would care because it confirms the continuation of the company's regular quarterly cash payout to investors.

FAQ

Frequently asked questions about ABBV stock

What is the ABBV stock price forecast for 2026-2027?

The 31 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $282, with estimates ranging from $200 to $328. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABBV stock a buy right now?

Of the 31 analysts covering AbbVie, Inc., 25 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 96 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABBV?

As at 12 Sept 2026, AbbVie, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will ABBV stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +9.7% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 96 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABBV stock forecast for 2030?

No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $328 over the next 12 months.

How has ABBV stock performed over the past year?

AbbVie, Inc. returned +20.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbbVie, Inc. do?

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases.

What is the latest news on ABBV?

The most recent item we track (The Motley Fool, 12 Sept 2026): "Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?". Billionaire investor Israel "Izzy" Englander more than doubled his stake in AbbVie stock, according to a Motley Fool article. The report also notes AbbVie is a diversified pharmaceutical company with a growing dividend that currently yields 2.7%.

Company

About AbbVie, Inc.

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.

CEO Mr. Robert A. Michael C.P.A. · 57,000 employees · United States · https://www.abbvie.com